News & Updates

Across the RADIANCE trials, individuals treated with renal denervation remain to have a lower medication burden throughout the 6-month follow-up period even after the reintroduction of blood pressure (BP)-lowering drugs.

A post hoc analysis of the CHANCE-2 randomized controlled trial (RCT) demonstrates that ticagrelor-aspirin combination therapy is associated with a significantly lower risk of new stroke within 90 days vs the clopidogrel-aspirin combination in Chinese CYP2C19 loss‐of‐function allele carriers with minor stroke or transient ischaemic attack (TIA) without intracranial artery stenosis (ICAS).

When combined with guideline-directed medical therapy, catheter ablation helps reduce the risk of adverse outcomes such as death, left ventricular assist device implantation, and urgent heart transplantation in patients with atrial fibrillation (AF) and end-stage heart failure, according to data from the CASTLE HTx study.

Use of apixaban appears to reduce the risk of gastrointestinal haemorrhage (GIH) compared with dabigatran, rivaroxaban, and vitamin K antagonist (VKA) in patients with nonvalvular atrial fibrillation, a recent study has shown. On the other hand, rivaroxaban use tends to increase GIH risk relative to dabigatran and VKA.

Weight loss induced by diet appears to improve biomarkers of endothelial function, according to a study. This intervention suggests a potential strategy to lower the risk of atherosclerosis.

Individuals with retinal artery occlusion (RAO) may be at increased risk of death, stroke, and myocardial infarction (MI) both in the short and long term, according to a study.